Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth
★★★★★ 3rd-party
External rating
- Source: Third-party data provider (Groww/CRISIL)
- Original rating: 3/5, displayed as-is — TopFund does not modify third-party ratings
- Refresh frequency: Whenever TopFund re-syncs this fund's data
- Limitations: The provider's own rating methodology isn't disclosed here — see the provider's own site for their criteria
TopFund Score: 73/100 · Good
How this score is calculated
- Star rating (35%)3/5
- 3Y CAGR (30%)22.23%
- Expense ratio (20%)1.05%
- AUM (15%)₹1,103 Cr
Not investment advice — an analytical read of public fund data. Methodology →
Aditya Birla Sun Life Mutual Fund · Equity · Sectoral
₹40.82
AUM: ₹1,102 Cr
NAV updated 18 days ago
Plan
Direct
Option
Growth
Risk
Very High
Expense Ratio
1.05%
Exit Load
Exit load of 1% if redeemed within 30 days.
Fund Manager
Dhaval Shah
Inception
Jul 2019
Benchmark
BSE Healthcare Total Return Index
Sharpe Ratio
1.53
Std Dev (1Y)
11.71%
Historical Returns (CAGR)
Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.
1m
+0.25%
3m
+9.5%
6m
+18.9%
1y
+19.08%
3y
+22.23%
5y
+14.63%
10y
—
since inception
+21.61%
TopFund's Take on Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth
Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth holds up reasonably well within the Sectoral category, currently carrying a 3-star rating. It has delivered steady, if unspectacular, returns over a full market cycle. TopFund's composite Health Score, which weighs rating, 3-year CAGR, expense ratio and fund size, puts it at 73/100.
Cost: At 1.05%, the expense ratio is roughly in line with the Sectoral category average of 0.99% — cost isn't a standout factor either way for this fund.
Risk-adjusted performance: Over the trailing 1-year period, the fund shows a strong Sharpe ratio of 1.53 — the fund has generated solid returns relative to the volatility it exposed investors to. Separately, annualised volatility of 11.71% is on the lower side for a Sectoral fund, suggesting a comparatively smoother ride.
Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Equity fund. Given the Very High risk rating, this fund is not suited to short-term goals or investors who may need to exit within 2-3 years.
This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.
Sector Allocation
Asset Allocation
Fund Snapshot
Similar Funds
DSP Nifty Healthcare Index Fund - Direct- Growth
DSP Mutual Fund
quant BFSI Fund - Growth Option - Direct Plan
Quant Mutual Fund
DSP Nifty Bank Index Fund - Direct - Growth
DSP Mutual Fund
Invesco India Financial Services Fund - Direct Plan - Growth
Invesco Mutual Fund
BANK OF INDIA Manufacturing & Infrastructure Fund-Direct Plan-Growth
Bank of India Mutual Fund
Bandhan BSE Healthcare Index Fund Direct Plan - Growth
Bandhan Mutual Fund
Tools & Guides for This Fund
Frequently Asked Questions about Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth
The current NAV (Net Asset Value) of Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth is ₹40.82. NAV is updated every business day after market close by AMFI.
1Y: 19.08% · 3Y CAGR: 22.23% · 5Y CAGR: 14.63%
The expense ratio of Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth is 1.05% per annum. This is the annual fee charged by the fund to manage your investment.
Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth is managed by Dhaval Shah at Aditya Birla Sun Life Mutual Fund.
Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth is classified as a Very High risk fund. It is suitable for aggressive investors with a long-term horizon of 5+ years.
Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth is a Sectoral fund. SIP suitability depends on your investment goal and risk profile.
You can start a SIP in Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth with as little as ₹500 per month through most mutual fund platforms. The minimum lump sum investment is typically ₹1,000.
The Assets Under Management (AUM) of Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth is ₹1,103 crore. AUM indicates the total market value of assets managed by the fund.
* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.
Discussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.